Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats

Neurobiology of Aging

Volumn 34, Issue 2, 2013, Pages 576-588

  Han, Wei Na ^a   Hölscher, Christian ^b   Yuan, Li ^a   Yang, Wei ^a   Wang, Xiao Hui ^a   Wu, Mei Na ^a   Qi, Jin Shun ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Alzheimer disease; Amyloid protein; CAMP; GLP l; Late phase long term potentiation; Liraglutide; Spatial memory

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CYCLIC AMP; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; LEARNING; LEARNING DISORDER; LONG TERM POTENTIATION; MALE; MAZE TEST; MEMORY DISORDER; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL LEARNING; SPATIAL MEMORY; UPREGULATION; VISION;

AMYLOID BETA-PEPTIDES; ANIMALS; CYCLIC AMP; EXCITATORY POSTSYNAPTIC POTENTIALS; GLUCAGON-LIKE PEPTIDE 1; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MEMORY; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84869090452     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.04.009     Document Type: Article

References (74)

1. Abbas T., Faivre E., Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res 2009, 205:265-271.
2. Abraham W.C., Mason S.E., Demmer J., Williams J.M., Richardson C.L., Tate W.P., Lawlor P.A., Dragunow M. Correlations between immediate early gene induction and the persistence of long-term potentiation. Neuroscience 1993, 56:717-727.
3. Arnold S.E., Hyman B.T., Flory J., Damasio A.R., Van Hoesen G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1991, 1:103-116.
4. Barria A., Muller D., Derkach V., Griffith L.C., Soderling T.R. Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation. Science 1997, 276:2042-2045.
5. Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
6. Cacace E., Manconi E., Binaghi F., Meloni M.C., Pitzus F., Carcassi U. [Etiopathogenesis and curative treatment of skin ulcer in intermediate beta-thalassemia]. Ann. Ital. Med. Int 1986, 1:47-53.
7. Chen Q.S., Kagan B.L., Hirakura Y., Xie C.W. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J. Neurosci. Res 2000, 60:65-72.
8. Clementi M.E., Pezzotti M., Orsini F., Sampaolese B., Mezzogori D., Grassi C., Giardina B., Misiti F. Alzheimer's amyloid beta-peptide (1-42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: an intriguing role for methionine 35. Biochem. Biophys. Res. Commun 2006, 342:206-213.
9. Cooke S.F., Bliss T.V. Plasticity in the human central nervous system. Brain 2006, 129:1659-1673.
10. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res 2007, 4:147-152.
11. Crouch P.J., Barnham K.J., Duce J.A., Blake R.E., Masters C.L., Trounce I.A. Copper-dependent inhibition of cytochrome c oxidase by Abeta(1-42) requires reduced methionine at residue 35 of the Abeta peptide. J. Neurochem 2006, 99:226-236.
12. Dalvi P.S., Nazarians-Armavil A., Purser M.J., Belsham D.D. Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro. Endocrinology 2012, 153:2208-2222.
13. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab 1995, 80:952-957.
14. Deshpande A., Mina E., Glabe C., Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci 2006, 26:6011-6018.
15. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med 2003, 9:1173-1179.
16. Ferreira I.L., Bajouco L.M., Mota S.I., Auberson Y.P., Oliveira C.R., Rego A.C. Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. Cell Calcium 2012, 51:95-106.
17. Ferreira S.T., Vieira M.N., De Felice F.G. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 2007, 59:332-345.
18. Gallwitz B. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinol 2006, 31:133-147.
19. Gengler S., McClean P.L., McCurtin R., Gault V.A., Hölscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 2012, 33:265-276.
20. Gibson G.E., Chen H.L., Xu H., Qiu L., Xu Z., Denton T.T., Shi Q. Deficits in the mitochondrial enzyme alpha-ketoglutarate dehydrogenase lead to Alzheimer's disease-like calcium dysregulation. Neurobiol. Aging 2012, 33:1121.e13-1121.e24.
21. Hamilton A., Hölscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009, 20:1161-1166.
22. Hamilton A., Patterson S., Porter D., Gault V.A., Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res 2011, 89:481-489.
23. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
24. Hölscher C. Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. Rev. Neurosci 2005, 16:181-212.
25. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat. CNS Drug Discov 2010, 5:109-117.
26. Hölscher C., Li L. New roles for insulin-like hormones in neuronal signaling and protection: new hopes for novel treatments of Alzheimer's disease?. Neurobiol. Aging 2010, 31:1495-1502.
27. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol 2004, 490:115-125.
28. Hunter K., Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012, 13:33-38.
29. Impey S., Mark M., Villacres E.C., Poser S., Chavkin C., Storm D.R. Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus. Neuron 1996, 16:973-982.
30. Itkin A., Dupres V., Dufrêne Y.F., Bechinger B., Ruysschaert J.M., Raussens V. Calcium ions promote formation of amyloid beta-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. PLoS One 2011, 6:e18250.
31. Iwai T., Ito S., Tanimitsu K., Udagawa S., Oka J. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci. Res 2006, 55:352-360.
32. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci 2002, 18:7-14.
33. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocr. Rev 1999, 20:876-913.
34. Li L., Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev 2007, 56:384-402.
35. Li S.F., Wu M.N., Wang X.H., Yuan L., Yang D., Qi J.S. Requirement of alpha7 nicotinic acetylcholine receptors for amyloid beta protein-induced depression of hippocampal long-term potentiation in CA1 region of rats in vivo. Synapse 2011, 65:1136-1143.
36. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., Tweedie D., Perry T., Mattson M.P., Kapogiannis D., Sambamurti K., Lahiri D.K., Greig N.H. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis 2010, 19:1205-1219.
37. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol 2009, 5:262-269.
38. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63:1187-1192.
39. Maurice T., Lockhart B.P., Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 1996, 706:181-193.
40. McClean P.L., Parthsarathy V., Faivre E., Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci 2011, 31:6587-6594.
41. Mehta M., Adem A., Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer's disease. Int. J. Alzheimers Dis 2012, 2012:728983.
42. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 1984, 11:47-60.
43. Nitta A., Fukuta T., Hasegawa T., Nabeshima T. Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn. J. Pharmacol 1997, 73:51-57.
44. Pan Y.F., Chen X.R., Wu M.N., Ma C.G., Qi J.S. Arginine vasopressin prevents against Abeta(25-35)-induced impairment of spatial learning and memory in rats. Horm. Behav 2010, 57:448-454.
45. Parihar M.S., Brewer G.J. Amyloid-beta as a modulator of synaptic plasticity. J. Alzheimers Dis 2010, 22:741-763.
46. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates: Hard Cover Edition 2007, Academic Press, London.
47. Perry T., Greig N.H. The glucagon-like peptides: a double-edged therapeutic sword?. Trends Pharmacol. Sci 2003, 24:377-383.
48. Perry T., Greig N.H. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res 2005, 2:377-385.
49. Perry T., Haughey N.J., Mattson M.P., Egan J.M., Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther 2002, 302:881-888.
50. Perry T., Holloway H.W., Weerasuriya A., Mouton P.R., Duffy K., Mattison J.A., Greig N.H. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol 2007, 203:293-301.
51. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., Greig N.H. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther 2002, 300:958-966.
52. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res 2003, 72:603-612.
53. Prediger R.D., Franco J.L., Pandolfo P., Medeiros R., Duarte F.S., Di Giunta G., Figueiredo C.P., Farina M., Calixto J.B., Takahashi R.N., Dafre A.L. Differential susceptibility following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice: evidence for a dissociation between cognitive deficits and the glutathione system response. Behav. Brain Res 2007, 177:205-213.
54. Qi J.S., Qiao J.T. Amyloid beta-protein fragment 31-35 forms ion channels in membrane patches excised from rat hippocampal neurons. Neuroscience 2001, 105:845-852.
55. Qi J.S., Qiao J.T. Suppression of large conductance Ca2+-activated K+ channels by amyloid beta-protein fragment 31-35 in membrane patches excised from hippocampal neurons. Sheng Li Xue Bao 2001, 53:198-204.
56. Qi J.S., Ye L., Qiao J.T. Amyloid beta-protein fragment 31-35 suppresses delayed rectifying potassium channels in membrane patches excised from hippocampal neurons in rats. Synapse 2004, 51:165-172.
57. Ryu J.K., McLarnon J.G. Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. Exp. Neurol 2006, 198:552-557.
58. Ryu J.K., McLarnon J.G. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. Neurobiol. Dis 2008, 29:254-266.
59. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev 2001, 81:741-766.
60. Stepanichev M.Y., Moiseeva Y.V., Lazareva N.A., Gulyaeva N.V. Studies of the effects of fragment (25-35) of beta-amyloid peptide on the behavior of rats in a radial maze. Neurosci. Behav. Physiol 2005, 35:511-518.
61. Strachan M.W., Reynolds R.M., Marioni R.E., Price J.F. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat. Rev. Endocrinol 2011, 7:108-114.
62. Terry A.V. Spatial Navigation (Water Maze) Tasks. Methods of Behavior Analysis in Neuroscience 2009, CRC press, Boca Raton, FL. 2nd edition. J.J. Buccafusco (Ed.).
63. Thal D.R., Rüb U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
64. Tran M.H., Yamada K., Nabeshima T. Amyloid beta-peptide induces cholinergic dysfunction and cognitive deficits: a minireview. Peptides 2002, 23:1271-1283.
65. Vella A., Shah P., Reed A.S., Adkins A.S., Basu R., Rizza R.A. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 2002, 45:1410-1415.
66. Vitolo O.V., Sant'angelo A., Costanzo V., Battaglia F., Arancio O., Shelanski M. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13217-13221.
67. Wang Q.W., Rowan M.J., Anwyl R. Inhibition of LTP by beta-amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP/PKA signaling pathway. Neurobiol. Aging 2009, 30:1608-1613.
68. Wang X.H., Li L., Hölscher C., Pan Y.F., Chen X.R., Qi J.S. Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 2010, 170:1239-1248.
69. Wimo A., Prince M. World Alzheimer Report 2010: the global economic impact of dementia 2010, Alzheimer's Disease International.
70. Wong S.T., Athos J., Figueroa X.A., Pineda V.V., Schaefer M.L., Chavkin C.C., Muglia L.J., Storm D.R. Calcium-stimulated adenylyl cyclase activity is critical for hippocampus-dependent long-term memory and late phase LTP. Neuron 1999, 23:787-798.
71. Yan X.Z., Qiao J.T., Dou Y., Qiao Z.D. Beta-amyloid peptide fragment 31-35 induces apoptosis in cultured cortical neurons. Neuroscience 1999, 92:177-184.
72. Ye C., Walsh D.M., Selkoe D.J., Hartley D.M. Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-d-aspartate (NMDA) versus non-NMDA receptor/channel activation. Neurosci. Lett 2004, 366:320-325.
73. Zhang J.F., Qi J.S., Qiao J.T. Protein kinase C mediates amyloid beta-protein fragment 31-35-induced suppression of hippocampal late-phase long-term potentiation in vivo. Neurobiol. Learn. Mem 2009, 91:226-234.
74. Zhang J.M., Wu M.N., Qi J.S., Qiao J.T. Amyloid beta-protein fragment 31-35 suppresses long-term potentiation in hippocampal CA1 region of rats in vivo. Synapse 2006, 60:307-313.